Compare BMM & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMM | EMBC |
|---|---|---|
| Founded | 2007 | 1924 |
| Country | Canada | United States |
| Employees | 68 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.3M | 354.1M |
| IPO Year | N/A | 2021 |
| Metric | BMM | EMBC |
|---|---|---|
| Price | $2.50 | $6.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $9.02 | $4.00 |
| AVG Volume (30 Days) | 533.9K | ★ 719.9K |
| Earning Date | 11-23-2026 | 11-24-2026 |
| Dividend Yield | N/A | ★ 0.65% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.59 |
| P/E Ratio | ★ N/A | $6.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.71 | $2.77 |
| 52 Week High | $8.63 | $14.78 |
| Indicator | BMM | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 27.08 | 43.28 |
| Support Level | N/A | $5.64 |
| Resistance Level | $6.58 | $6.85 |
| Average True Range (ATR) | 0.36 | 0.36 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 6.08 | 19.31 |
Blue Moon Metals Inc is a Canadian exploration stage company focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The projects of the company include the Nussir copper-gold-silver property in Norway (the "Nussir Property"), the Blue Moon zinc-copper-gold-silver property in California, USA (the "Blue Moon Property"), the NSG copper-zinc-gold-silver property in Norway (the "NSG Property") the Springer tungsten-molybdenum project in the Nevada, USA (the "Springer Property") and the Apex germanium-gallium-copper project in Utah, USA (the "APEX Property").
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.